Squarepoint
LCTX icon

Squarepoint’s Lineage Cell Therapeutics LCTX Stock Holding History

Squarepoint’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$583K Buy
444,774
+301,584
+211% +$417K ﹤0.01% 3308
2026
Q1 		$226K Buy
143,190
+78,081
+120% +$132K ﹤0.01% 3895
2025
Q4 		$109K Buy
+65,109
New +$113K ﹤0.01% 4027
2025
Q3 		– Sell
-511,107
Closed -$464K – 4701
2025
Q2 		$464K Buy
511,107
+153,335
+43% +$91K ﹤0.01% 3335
2025
Q1 		$162K Buy
357,772
+265,771
+289% +$156K ﹤0.01% 4089
2024
Q4 		$46.2K Buy
+92,001
New +$67.5K ﹤0.01% 4858
2024
Q3 		– Sell
-44,307
Closed -$44.2K – 4422
2024
Q2 		$44.2K Sell
44,307
-147,588
-77% -$163K ﹤0.01% 3916
2024
Q1 		$284K Buy
191,895
+18,597
+11% +$21.1K ﹤0.01% 3435
2023
Q4 		$189K Buy
173,298
+148,667
+604% +$163K ﹤0.01% 3619
2023
Q3 		$29.1K Sell
24,631
-7,294
-23% -$9.92K ﹤0.01% 3679
2023
Q2 		$45K Sell
31,925
-931
-3% -$1.29K ﹤0.01% 3449
2023
Q1 		$49.3K Buy
+32,856
New +$45.9K ﹤0.01% 3064

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Squarepoint's LCTX Position: Q2 2026 in Review

Squarepoint increased its Lineage Cell Therapeutics (LCTX) stake by 211% in Q2 2026, buying an estimated $417K and bringing the position to 444,774 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #3308.

Squarepoint first reported a position in LCTX in Q1 2023 and has held it in 12 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Squarepoint held 444,774 shares of Lineage Cell Therapeutics worth $583K as of Q2 2026.
  • Squarepoint bought 301,584 Lineage Cell Therapeutics shares in Q2 2026, an estimated $417K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3308 holding.
  • Squarepoint first reported a position in Lineage Cell Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.